O'Malley J P, Illingworth D R
Department of Medicine, Oregon Health Sciences University, Portland 97201.
Metabolism. 1990 Feb;39(2):150-4. doi: 10.1016/0026-0495(90)90068-n.
Apolipoprotein E (apo E) phenotypes have been previously shown to influence plasma lipoprotein concentrations in normal populations and to affect the response to some lipid lowering drugs. The purpose of the present study was to determine if variations in the apo E phenotype also affect basal lipoprotein concentrations in patients with heterozygous familial hypercholesterolemia (FH) and if the apo E phenotype influenced their subsequent response to lovastatin. Apo E phenotypes were determined on plasma from 134 FH patients. The relative frequencies of the epsilon 2, epsilon 3, and epsilon 4 alleles were .090, .772, and .138, respectively. Plasma triglycerides were found to be 34% higher in E3/2 heterozygotes relative to E3/3 patients. Baseline concentrations of low-density lipoprotein (LDL) cholesterol in untreated FH patients were not influenced by the apo E phenotype; the hypolipidemic response to lovastatin (20 or 40 mg twice daily) was also independent of the apo-E phenotype of the patients.
载脂蛋白E（apo E）表型先前已被证明会影响正常人群的血浆脂蛋白浓度，并影响对某些降脂药物的反应。本研究的目的是确定apo E表型的变异是否也会影响杂合子家族性高胆固醇血症（FH）患者的基础脂蛋白浓度，以及apo E表型是否会影响他们随后对洛伐他汀的反应。对134例FH患者的血浆进行了apo E表型测定。ε2、ε3和ε4等位基因的相对频率分别为0.090、0.772和0.138。发现E3/2杂合子患者的血浆甘油三酯比E3/3患者高34%。未治疗的FH患者的低密度脂蛋白（LDL）胆固醇基线浓度不受apo E表型影响；对洛伐他汀（每日两次，20或40毫克）的降血脂反应也与患者的apo-E表型无关。
